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ABSTRACT
Background: With an ageing HIV-positive population,
sub-Saharan Africa is now facing a dual epidemic of
communicable and non-communicable diseases
(NCDs). This study aimed to assess trends in the
prevalence of hypertension and factors associated with
hypertension, among adults attending an ambulatory
HIV clinic in Kampala, Uganda.
Methods: We conducted a retrospective chart review
to identify patients with hypertension. We used a
random number generator to select 400 patient charts
from each year from 2009 to 2014. Blood pressure,
age, body mass index (BMI), WHO disease stage and
Karnofsky scores were extracted. Logistic regression
was used to estimate the strength of the association
between each of these factors and the presence of
hypertension.
Results: In total, 1996 charts were included in this
analysis. The mean age of participants was 31 years
and 1311/1996 (65.7%) were female. The overall
prevalence of hypertension was 418/1996 (20.9%).
This rose from 16.9% in 2009 to 32.3% in 2013. Of
the patients with hypertension, 96/418 (23.0%) were
receiving adequate treatment. Patients >50 years of age
had 3.12 times the odds of hypertension compared
with patients aged 20–29 years (95% CI 2.00 to 4.85).
Men had 1.65 times the odds of hypertension
compared with women (95% CI 1.34 to 2.03) and
patients with a BMI of 35–39 kg/m2 had 3.93 times the
odds of hypertension compared with patients with a
BMI <25 kg/m2.
Conclusions: The prevalence of hypertension is rising
in the Ugandan HIV-positive population. There remains
inadequate management and control of hypertension in
this group highlighting the need to better integrate
NCD care within the HIV clinical settings.
INTRODUCTION
There has been a substantial reduction in
HIV-associated morbidity and mortality as a
result of the global scale-up of antiretroviral
therapy (ART). This is particularly true in
low and middle income countries, such as
those in the sub-Saharan African region,
which bear the largest burden of HIV.1–4
This reduction in mortality has substantially
increased life expectancy, with estimates now
approaching that of the general popula-
tion.5–8 Now that HIV-positive individuals are
living longer lives, there has been increased
attention towards the emerging dual burden
of HIV and non-communicable diseases
(NCDs), such as hypertension.
Key questions
What is already known about this topic?
▸ With advancements in HIV treatment and care,
morbidity and mortality associated with HIV
have decreased in many limited resource
settings.
▸ Since people are living longer lives and experi-
encing less complications as a result of HIV,
patients are now presenting to primary care pro-
viders with non-communicable diseases, includ-
ing hypertension.
▸ At the population level, there is mixed evidence
from low and middle income countries on the
prevalence of hypertension among HIV-positive
patients and its correlates.
What are the new findings?
▸ We retrospectively performed a chart review on
1996 patients from 2009 to 2013 to identify
hypertension and correlates among patients
attending an ambulatory HIV clinic in Kampala,
Uganda.
▸ The overall prevalence of hypertension was 418/
1996 (20.9%). This rose from 16.9% in 2009 to
32.3% in 2013.
Recommendations for policy
▸ There is a need to better integrate NCD care
within the HIV clinical settings.
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Research
Hypertension in HIV-positive patients has been
reported to be as low as 8.7% and as high as 45.9% in
low and middle income countries.9 10 Compared with
the general population, some studies have suggested
that hypertension is more prevalent among HIV-positive
patients,9 11 whereas other studies have reported that
patients with HIV have lower levels of hypertension,
compared with the general population.12 13 Although
there has been a comparable response to therapy for
patients with hypertension with or without HIV infec-
tion,9 the dual burden of NCDs and HIV provides a
challenge to weak healthcare systems in low and middle
income countries.14 Establishing the magnitude of
hypertension among HIV-positive patients and docu-
menting the quality of care for these conditions within
the HIV care setting provides an opportunity for
improved care. The aim of this study was to determine
the prevalence of hypertension, trends and associated
factors among adults attending an ambulatory HIV
clinic from 2009 to 2013 in Kampala, Uganda.
METHODS
Study design and population
This was a retrospective study conducted at the Mulago
AIDS Clinic, an outpatient clinic of Makerere University
Joint AIDS Programme (MJAP), located in Kampala,
Uganda. This clinic, supported by the President’s
Emergency Plan for AIDS Relief (PEPFAR), provides
comprehensive HIV services to over 14 000 HIV-positive
individuals, with the majority over the age of 18 years.
Most of the patients live within a 20 km radius of the
clinic. The HIV treatment guidelines (2014) at the clinic
at the time of the study included eligibility for all
patients with a CD4+ T-cell count of ≤500 cells/mm3, or
the presence of WHO clinical disease stage 3 or 4, preg-
nancy, hepatitis B co-infection, HIV-associated nephropa-
thy, or patients under 15 years of age. The clinic follows
the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure ( JNC-7) clinical guidelines for the
detection and management of hypertension.
Patients were eligible for inclusion if they were at least
18 years of age and visited the clinic between 2009 and
2014. Patients were randomly selected based on their
year of intake into the HIV clinic and each patient was
given a unique identiﬁer at enrolment, so that patients
do not appear on more than one sampling frame for
each year. From this sampling frame, 400 patient charts
from each year were randomly selected using a random
number generator. For each of the 400 patient ﬁles
selected, study variables were extracted.
Study variables
The primary outcome variable was prevalence of hyper-
tension. In each year, patients were considered as hyper-
tensive if their systolic blood pressure ≥140 mm Hg
and/or diastolic blood pressure ≥90 mm Hg at three
consecutive measurements separated by at least 2 weeks
and taken after 5–10 min of rest in a sitting position or
if they were known to be hypertensive and on treat-
ment.15 Adequate control for hypertension was deﬁned
as systolic blood pressure <140 mm Hg and diastolic
blood pressure <90 mm Hg at the second and successive
visits.15
Additionally, we extracted data on demographic, clin-
ical and biological characteristics including: WHO HIV
disease stage, whether the patient was on ART, body
mass index (BMI) and Karnofsky score that measures
the degree of patient’s functional impairment on a scale
of 0–100.
Statistical analysis
Descriptive statistics were used to characterise the data.
Prevalence of hypertension was calculated as the propor-
tion of the study sample with a positive diagnosis,
overall, and in each study year. Bivariable logistic regres-
sion was used to estimate the strength of the association
between each study variable and the primary outcome,
hypertension. A multivariable logistic model, adjusted
for age and sex, was also constructed. Results are pre-
sented as ORs and adjusted ORs along with associated
Table 1 Demographic and clinical factors stratified by
hypertension
No
hypertension Hypertension
n (%) n (%) p Value
Age, years
<20 41 (2.7) 5 (1.0) <0.001
20–29 578 (38.2) 144 (29.9)
30–39 629 (41.5) 191 (39.7)
40–49 213 (14.1) 99 (20.6)
>50 54 (3.6) 42 (8.7)
Sex
Female 1036 (68.3) 273 (56.6) <0.001
Male 481 (31.7) 209 (43.4)
BMI, kg/m2
18–24 1184 (78.8) 329 (68.4) <0.001
25–29 222 (14.8) 97 (20.2)
30+ 74 (4.9) 37 (7.7)
On ART
No 281 (18.5) 78 (16.2) <0.001
Yes 1236 (81.5) 404 (83.8)
WHO HIV disease stage
Stage 1 and 2 1066 (70.3) 385 (79.9) <0.001
Stage 3 and 4 451 (29.7) 97 (20.1)
Karnofsky score
0–80 122 (9.6) 14 (3.6) <0.001
81–100 1146 (90.4) 371 (96.4)
ART, antiretroviral therapy; BMI, body mass index.
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95% CIs. All statistical tests were two-sided with α set at
0.05. Analyses were performed using STATA V.12
(StataCorp, College Station, Texas, USA).
RESULTS
In total, 2000 (400 per year from 2009 to 2013) patients
were randomly selected from a sampling frame of
13 550. In 2009, four patients did not have any informa-
tion on the outcome, so the ﬁnal analytic sample con-
sisted of 1996 patients. Of these, 418 were considered
hypertensive, an overall study prevalence of 20.9%.
Table 1 displays patient demographic and clinical factors
stratiﬁed by the presence of hypertension, while table 2
displays the characteristics of the sample by each year
sampled.
Figure 1 shows the prevalence of hypertension by
study year. Each year, the prevalence of hypertension
increased. The prevalence in 2009 was 67/396 (16.9%),
in 2010 was 76/400 (19.0%), in 2011 was 96/400
(24.0%), in 2012 was 114/400 (28.5%), and in 2013 was
129/400 (32.3%). Of the patients with hypertension,
96/418 (23.0%) were receiving adequate treatment. The
proportion of adequately treated patients rose from 14/
53 (26.4%) in 2009 to 37/105 (35.2%) in 2013. Men
had a higher prevalence of hypertension each year com-
pared with women.
Table 3 displays the results of bivariable and multivari-
able logistic regression to estimate the strength of the
association between each demographic and clinical
factor and the presence of hypertension. Patients
>50 years of age had 3.12 times the odds of hypertension
compared with patients aged 20–29 years (95% CI 2.00
to 4.85). Men had 1.65 times the odds of hypertension
compared with women (95% CI 1.34 to 2.03) and
patients with a BMI of 35–39 kg/m2 had 3.93 times the
odds of hypertension compared with patients with a
BMI <25 kg/m2. Patients with a WHO disease staging of
3 or 4 had 0.60 times the odds of hypertension com-
pared with patients with stage 1 or 2 (95% CI 0.46 to
0.76) and patients with a Karnofsky score of 81–100 had
2.82 times the odds of hypertension compared with
patients with a score of 0–80 (95% CI 1.66 to 5.19).
After adjusting for age and sex, the adjusted ORs
changed minimally, indicating that confounding had a
minimal inﬂuence on the model.
DISCUSSION
This study sought to determine the prevalence, trend
and correlates of hypertension among adults attending
an ambulatory HIV clinic in Kampala, Uganda. We
found a rise in the prevalence of hypertension from
2009 to 2013, from 16.9% to 32.2%. Similarly, HIV
prevalence rose from 6.4% in 2005 to 7.3% in 2014
Table 2 Sample characteristics by year, 2009–2013
n
p Value2009 2010 2011 2012 2013
Mean age (SE) 33.7 (0.5) 34.1 (0.4) 33.5 (0.4) 32.4 (0.5) 31.7 (0.5) —
Age, years
<20 8 3 4 6 25 <0.001
20–29 139 124 135 176 148
30–39 164 182 173 144 157
40–49 62 71 65 53 61
>50 25 20 21 20 10
Sex
Female 250 246 269 271 273 0.154
Male 148 154 129 128 131
BMI, kg/m2
18–24 332 324 291 286 280 <0.001
25–29 45 52 77 80 65
30+ 20 22 24 31 55
WHO HIV disease stage
Stage 1 and 2 258 264 279 316 334 <0.001
Stage 3 and 4 140 136 119 83 70
Karnofsky score
0–80 32 68 9 9 18 <0.001
81–100 365 331 64 389 368
BMI, body mass index.
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(The Joint United Nations Programme on HIV/AIDS
(UNAIDS), Gap Report). This demonstrates a rising
double burden of HIV and hypertension, consistent with
reports that as the proportion of HIV-positive patients
achieving viral suppression on combination ART grows
larger and these patients age, they are experiencing a
widening spectrum of non-AIDS-related diseases.1
Our study found an overall prevalence of 24.1% and a
rising prevalence by year from 16.9% in 2009 to 32.3%
in 2013. This is most likely due to the rising age of the
patients accessing HIV care as well as the number of
patients being put on antiretroviral therapy (ART).
There might also be other factors which may not have
been uncovered by the current study due to its retro-
spective nature. Compared with the general population
in Uganda, the prevalence of hypertension in
HIV-positive adults is within a similar range (21.2% vs
27.2%).16 Mateen et al10 in Uganda similarly reported a
28% prevalence of hypertension and 49% in those
above 50 years with similar risk factors. In another
Ugandan study, Sander et al9 reported a lower preva-
lence of hypertension 8.0%, although when they consid-
ered only one elevated blood pressure reading, the
prevalence rose to 26.3%. In contrast to Sander et al,9
where 83% of participants diagnosed with hypertension
were on antihypertensive medications, in our study only
20.9% were on recommended treatment for hyperten-
sion. In both studies, the most commonly used drugs
were β-blockers and calcium channel blockers.9
Our results provide evidence that hypertension has
become an important NCD in the HIV-positive popula-
tion with prevalence rates similar to that of the general
population. In addition, our study shows that manage-
ment of HIV-positive patients with hypertension is still
inadequate. This is partly explained by the current HIV
care guidelines in Uganda, which do not routinely
include an NCD programme for HIV-positive patients
attending the ambulatory clinics. Furthermore, most of
the effort from the government and international agen-
cies is currently focusing on HIV, tuberculosis and
malaria, with less attention to the rising burden of hyper-
tension in the HIV ageing population. Justice1 recom-
mends that focus must shift from a narrow interest in
CD4 counts, HIV RNA and AIDS deﬁning illnesses to
determining the optimal management of HIV infection
as a complex chronic disease in which the causes of mor-
bidity and mortality are multiple and overlapping. We
need a new paradigm of care with which to maximise
functional status, minimise frailty and prolong life expect-
ancy.1 The authors propose a composite index that sum-
marises a patient’s risk of morbidity and mortality.
In this era of an ageing sub-Saharan African popula-
tion on ART, we expect more patients to present with
hypertension and other chronic conditions. This has
become a substantial burden on resource-limited coun-
tries to manage a dual epidemic of infectious and
chronic diseases. Few NCD programmes have been
incorporated into HIV care and this highlights the
Figure 1 Overall prevalence of
hypertension by year of chart
review. Note: Table indicates
number of patients each year with
each systolic blood pressure
(SBP) ≥140 mm Hg or diastolic
blood pressure (DBP)
≥90 mm Hg, as well as
SBP≥140 mm Hg and
DBP≥90 mm Hg.
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importance of implementing screening, early diagnosis,
and prevention measures for hypertension and other
chronic diseases.
Our study has several strengths. The study was con-
ducted in an ambulatory clinic, which serves a large pro-
portion of the patients with HIV in urban Uganda.
However, MJAP, being a centre of excellence in HIV,
may not truly reﬂect what is happening elsewhere in the
country where the access to expert service care may be
more limited. Although we cannot use these data from a
specialised urban HIV clinic to generalise hypertension
care in Uganda, the ﬁndings demonstrate a missed
opportunity for comprehensive care even among
patients who frequently interface with healthcare provi-
ders. The ﬁndings therefore highlight a need for health-
care providers to develop indicators which can be used
to monitor for improved care beyond HIV, in
HIV-infected individuals with comorbidity. Additionally,
the interpretation of our results must take into account
some limitations. Most importantly, this was a chart
review study and no patients were contacted; therefore,
there were only a limited number of variables to extract
and consider in the analysis. In particular, data on
lifestyle factors important to hypertension, such as
smoking status and alcohol intake, were sparse and not
usable. Therefore, only a limited number of variables
were available to construct a bivariable and multivariable
model.
In conclusion, our study corroborates other studies
that suggest an increasing prevalence of hypertension
among HIV-positive patients in Uganda. Identifying risk
factors will be important for clinicians to adequately
manage a growing dual epidemic of infectious and
chronic diseases in sub-Saharan Africa.
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